SK38293A3 - Copposition for the substained and controlled release of a medicinal peptidecontaining substance and preparation method thereof - Google Patents
Copposition for the substained and controlled release of a medicinal peptidecontaining substance and preparation method thereof Download PDFInfo
- Publication number
- SK38293A3 SK38293A3 SK38293A SK38293A SK38293A3 SK 38293 A3 SK38293 A3 SK 38293A3 SK 38293 A SK38293 A SK 38293A SK 38293 A SK38293 A SK 38293A SK 38293 A3 SK38293 A3 SK 38293A3
- Authority
- SK
- Slovakia
- Prior art keywords
- peptide
- water
- salt
- formula
- insoluble
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000000126 substance Substances 0.000 title abstract description 4
- 238000013270 controlled release Methods 0.000 title abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000004005 microsphere Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002546 agglutinic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Vynález sa týka zmesí určených k. predĺženému a kontalovanému uvolňovaniu liečivej peptidovej látky vzorca J.
Ac?~D-Nal--D-pClF'he.....FP -Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NUs v ktorom R3 znamená P-F'al alebo D-Trp„
Také peptidy sú analógmi LHRH a močno ich s výhodou P o uživ a ť p r i t e r a p e u t i c k o m 1 i e č e n í h o r m o n á 1 n e závisí, ý c h P r o b 1. é m o v „ A k n i e j e u v e d e n é i n a k , o 2 n a č u j ú s a a m i n o k y s e 1 .i. n y v zhora uvedenom vzorci I zvyčajným spôsobom a majú konfiguráciu L, D-Na.l znamená D-3~ í Ξ-n a f tyl )a.l ani n a D-F’al z n a m e n á D - 3 -· í 3 - .p y r ;i. d y 1) a 1 a n í n .
Vynález sa týka tiež spôsobu pripravý zhora definovanej zmesi.
Doteraz boli navrhované rôzne roztoky pre prípravu zmesí k p r' e d í ž e n é m u a k o n t r o ]. o v a n é m u u v o 1 ň o v a n j., u 1 .i. e č i v ý c h 1 á t o k ·, pričom sa vyrábajú biodegradovatelné implantáty, mikroskopické zapúzdrenia alebo sa priprávjú pórovité biodegradovatelné matrice vyskytjúce sa napríklad vo forme m .i k. r o g u 1 i č i e k a lebo m i k r o č a s t i c r ô z n y c h v e ľ k o s t í K t ý m t o riešeniam je tu možné citovať EP A 0,052 510, zaoberajúci sa mikrozapúzdrovanim sa separáciou fáz vodorozpustných drog, a EP A 0 05S 481 alebo US A 3 976 071 pre prípravu implantátov alebo pórovitých biodegradovatelných matríc v podstate na báze poly lak t i d u alebo k o-pol y laktid-gl y kol i d u,. Pri týchto postupoch sa biodegrádováteIný polymér alebo kopolymér rozpustí vopred v organickom rozpúšťadle a použije sa potom samo t n á 1 i. e Č i v á 1 á t k a „ a k. o n o s i č , p r i p a c! ne s a r o z. p u s; t í
F’r i iných postupoch vedúcich tiež k tvorbe mik.ro k a psi í alebo mikrogul ičiek sa používa, emul gácia. Základná fáza t a k ý c h t o p o stu p o v s p o č í v a v z í s k a n í e m u 1 z .i. e t y p u o 1 e j v o - v o d e , p r i č: o m s a v y c h á d z a z o r g a n i c k é h o r o z t o k u polymérnej látky a z vodného roztoku peptidu, vi z US-A-4 384 975, 3 891 570, 4 389 330, 3 737 337, 4 652 441 alebo w o -90 /13361, V o v é e t k ý c h p r i p a d o c h j e s n a h a v y v i n ú ť k. o m p 1 e n é & ľahko uskutočniteIné postupy, aby sa zabránilo čo najviac stratám aktívnych peptidových látok, obzvlášť rozpustných vo vode, ako je tomu napríklad pri dvojitej emulgácií.
Ak sa v priebehu niektorého z takých postupov jedná o vytváranie emulzie typu olej vo vode s následným premiestnením do vodného prostredia, umožňuje postup podľa t o h t o v y ľi á 1 e z u p r o t i v š e t k ý m o č a k á v a n i a m p r e k o n a ť v ý h o d n ý m z pôsobom nedostatky doteraz známy c h tec hn ic kýc h postupov..
pQ.dÄÍ;^i.ä_Ji.yiiá.Lezu
Podstata zmesi podľa tohto vynálezu je v tom, že je vo f o r m e m i k r o s k o p i c k ý c h g u 1 i č i e k p o 1 y m é ľ n e ľ'i o b i. o 1 o g i c:: k y degradovatelného materiálu, ktorý obsahuje vo vode nerozpustnú soľ peptidu vzorca ITakáto zmes, obsahujúca n a p r í k 1 a d a s p o ň 5 7 h m o t n o s t n ý c h n e? ľ” o z p u s t n e j s o 1 i , v z a t é n a h m o t n o s ť p o 1 y m é r n e h o b i o d e g r a d o v a t. e 1 n é h o m a t e r i á 1 u, m ô ž e uvolňovať peptid vzorca I kontrolovaným zpôsom v čase trvania, niekoľko dri í po jej podaní parenterálnou cestou človeku alebo zvieraťu.
Podstata zpôsobu podľa tohto vynálezu pre; prípravu zhora definovanej zmesi spočíva v tom, že sa soľ peptidu vzorca I, ktorá je rozpustná vo vode, premení najprv na soľ peptidu, ktorá, je vo vode nerozpustná, načo sa uvedená nerozpustná soľ peptidu prevedie do suspenzie v roztoku polymérnej b i o d e g r a d o v a t e 1 n e j 1 á t k y, č í m s a u v e d e n á s u s p e n z i. a p r e m e n í v e m u 1 s. i u t y p u o I e j v o v o d e a n a k o n i e c: s a m i k r o g u 1 i č k y biodegradovatelného polyméra izolujú po prevedení emulzie o 1 e j a v o v o d e d o p r o s t r e d i a s n a d b y t k o m v o d y „
P r e d o v š e t k ý (n p r i p o s t u p e k o n v e r z i e p e p t i d o v e j vodorozpustnej soli na soľ peptidu nerozpustnú vo vode poskytuje vynález skutočne obzvlášť originálne riešenie, pri ktorom sa využíva výhod plynúcich z pomerne rozdielnych r o z p lis tn o s t í p o u S i t ý c h z 1 o 2 i e k , h 1 a v n e p o t o m p o u 2 i t ý o h r o z p ú š ť a d i e 1 a ne r o z p ú š ť a d i e 11'
Zpôsob podľa tohto vynálezu spočíva v tom, že sa
a) s o ľ p e p t i d u v z o r c. a I r o z p u s t n á v o v o d e .p r e m e n í n a s o ľ peptidu nerozpustnú vo vode, b ) u v e d e n á., vo v o d e n e r o z p u s t n á s o ľ p e p t i. d u s a p r e v e d i e do suspenzie v organickom prostredí obsahujúceho polymérny biodegradovatelný materiál v rozpustenom stave,
c) uvedená organická suspenzia sa disperguje vo vodnom prostredí za vzniku súvislej vrstvy výslednej emulzie a
d) uvedená emulzia sa premiestni do nadbytku vodného prostredia a nakoniec sa z vodnej vrstvy oddelia takto z í s k a n é m i k r o g u 1 i č k y .
F'rvá fáza postupu spočíva v premene, za použitia zvyčajnej techniky, soli peptidu rozpustnej vo vode na soľ peptidu, ktorá je vo vode nerozpustná, Výrazom rozpustná vo vode sa myslí peptidová soľ, ktorej rozpustnosť vo vode je väčšia alebo rovná 0,1 mg/1 pri 25°C, s výhodou väčšia alebo rovná 1,0 mg/1.
Termínom nerozpustná vo vode sa myslí peptidová soľ majúca rozpustnosť vo vode menšiu alebo rovnú 0,1 mg/1 pri 25°C, Tejto definícií vyhoujú soli peptidov tvorené pamoátom, t a n n á t o m, s t e a r á t o m a 1 e b o p a 1 m i t á t o m,
Ako polymérny biologicky degradovatelný materiál sa P o u ž í v a p o 1 y 1 a k t i d, poly g 1 y k o 1 i d a 1 e b o k o p o 1 y m é r k y s e 1. i n y mliečnej a glykólovej.
Ako polymérny materiál, ktorému sa dáva prednosť, je n u t n é u v i e <-> ť l< o r o 1 y m é r y k y s e 1 i n y m 1 i e č n e j a k y s e 1 i n y glykolovej (F'LGA), zvlášť potom kopolvrnéry kyseliny L- alebo
D, L -·- m 1 i e č n e j o b s a h u júci. 45 a J m o 1 % j e d n o t i. e k k y s e 1 i n y mliečnej, poprípade 45 až 10 mol jednotiek kyseliny glykolovej A k o r o z p ú š ť a d 1 o p r e z v o 1 e n ý p o 1 y m é r n y m a t e r i á 1 s a p o u ž í v a a k o j e n a p r í k 1 a d m e t h y 1 é n c h 1 o r i d n V o tu jedná o rozpúšťadlo, ktoré sa nechová ako nerozpúšťadlo k obsahovanej peptidovej soli.
Akonáhle sa uvedená soľ uvedie podľa vynálezu do suspenzie materiálu v o ľ“ g a n i. c k é r o z p ú š ť a d 1 o, v š e t k ý c h p r í p a d o c h s a v roztoku rozpúšťadle, množstva vhodnou polymérneho organickom vleje sa táto suspenzia do vopred stanoveného pridanej s cieľom je?
v o d n é h o p r o s t: r e d i. a, o b v y k 1 e d o v o d y P o v r c h o v o a k t í v n o u 1 á t k o u „ Z a m ý š ľ a n ý m v y t v o r i ť r ý c h 1 o h o m o g é n n u e m u 1 z i. u t y p u o lej v o v o d e, p r i č o m uvedené vodné prostredie slúži, ako plynulá fáza,, Prípravu takejto emulzie ovplyvňujú rôzne činitele, ktorých vplyvom sa upravuje? tvar alebo štruktúra mikroguličiek vznikajúcich pri tomto postupe. Jedným z týchto činiteľov, na ktorý je treba brať ohľad, je rýchlosť pridávania organického roztoku do vodného prostredia, inou závažnou okolnosťou tu môže byť teplota alebo ešte? rýchlosť miešania alebo energia disperzie? (sonifikácia), Posledne uvedený parameter má vplyv zvlášť na t v a r k o n e č n ý c h m i k r o s k c? p i c k ý c h g u 1 i. č i. e k „ J e t a z á 1 e S i t o s ť o u odborníka v tomto odbore zvoliť k sledovanému účelu vhodné postupové metódy a podmienky pre emulgáciu.
Pri uskutočňovaní uvedenej emulgácie môže byť taktiež výhodné upraviť objemový pomer existujúcich fáz, zvlášť zmenšiť počiatočný objem organickej fázy k vodnej fáze. V dannom prípade, vzhľadom k prchavosti použitých organických r o z p ú š ť a d ;i. e 1, n a p r í k 1 a d m e t h y 1 c Ιί 1 o r i d u, n a s t á v a s p o n t á n n e odparovanie v dobe, keď sa miešanie javí byť už ako dostatočné, inak sa žiadaný jav môže urýchliť tým, že sa použije čiastočného odparovania za zníženého tlaku.
A k o n á h 1 e s a o r g a n i c k o - v o d n á s t a t) i 1 j. z o v a n á e m u 1 z i. a p r i d á do nadbytočného vodného prostredia, najčastejšie do vody n a s t á v a t u h n t..i t .i. e z á r o d k o v ý c h m i k r o g u 1 i č i e k , v y t v A r a j ú c: .i. í;: h s a v e m u 1 z i í , e t r a k c i. o u. o r g a n i o k é h o r o z p ú. š ť a d I a , k t o r é j e e š t e prítomné v uvedených mikoguličkách. Touto operáciu sa tiež o d s t r á n i a s ú č a s n é s t o p y e š t e p r í t o m n é h o p o v r c h o v o a k t í v n e h o činidla, ktoré by mohli byť obsiahnuté v hmote polyméra počas konečného tuhnutia,, Poznamenáva sa, že voda je '' n e r o z p ú š ť a d 1 o m a k o p r e po 1 y en é r n y b i o d e g r a d o v a t e 1 n ý materiál, ako napríklad F'LGA, tak aj pre peptidovú soľ o b s i a h n u t ú v o v r i ú t r i u v e d e n ý c h m i k r o g u 1 i č i e k» T á t o s i t u á c i a takto uľahčuje nutnú extrakciu rozpúšťadla, napríklad CH2CI2, usadeného v plymére.
P o p r' i d a n í í..s v e d e n e j e m u 1 z i e d o n a d b y t k u v o d n é h o prostredia, oddelia sa vytvrdené mikroguličky zvyčajnými P o s t u p· m i , n a p r í k 1 a d o d s t r eďo v a n í m, f i 11 r á c i o u a 1 e b o dekantáciou, Mi krogul ičky sa tiež prepláchnu, vyčistia a usušia.
J e d n o u z v ý ho d po s tupu p od ľ a to h to v y n á 1 e z u j e, ž e umožňuje získavať mikroguličky, ktorých tvar je možné presne kontrolovať, pričom sa táto kontrola uskutočňuje hlavne v čase prípravy emulzie (napríklad voľbou rýchlosti miešania). Iná výhoda je najmä v zväčšenej dávke peptidu, ktorá môže byť v jednotlivých p r á pádoch 5, 10 a dokonca 20 7, hmotnostných.
Okrem toho sa obzvlášť zväčšuje stupeň vpravenia peptidu alebo jeho soli, toto nastáva najmä vplyvom predchádzajúcej premeny vodorozpustnej pept.i dovej soli na soľ nerozpustnú vo vode,
Mikroguličky získané zpôsobom podľa tohto vynálezu zo zhora u v e d e ný ch z I o ž i e k sa po tom mô ž u používať, po pri me ran e j sterilizácií, k príprave suspenzií určených k podávaní p a r e n t e r á 1 n y m z p ô s o b o m, n a p r í k 1 a d .1 n t r a m u s k u 1 á r n y m i a 1 e b o s u b k u t á n n y m i i n j e k c i a m i ,,
Vynález je ďalej bližšie objasňovaný na nasledujúcich príkladoch, ktoré však vynález v žiadnom prípade neobmedzujú,,
F' r i k 1 a d y p r- e v e d e n i a v v n Á1 e z u
Príklad 1 g octanu analógu LHRH vzorca Ac-D-Na 1 -D-pC 1 Phe-D-Pa 1 -Ser-Ty r-D-Ci t-Leu-Ar g-Pro-D-A 1 a~NH2 sa premenia na zodpovedajúci pamoát známymi postupmi a spracuje sa tak, aby sa. získali častice s priemernou veľkosťou pribi ižne 10 mikrónov,,
0,317 g uvedeného pamoátu a 1,683 g F'LGA 75 s 25 (mol a) sa prevedie do suspenzie 20 ml CH2CI2. Potom sa uvedená suspenzia pridá k 20 ml methylénchloridu, ktorý obsahuje v rozpustenom stave 1,683. g k o pol y móra kyseliny .0,1....--· ml iečnej a g 1 y k o 1 o v e j ( P L G A ) 7 5 s 2 5 ( m o 1 Z, s v n ú t o r n o u v i z k o z i t o u 0,8 2 v HFIF’)» Zmiešanie sa robí pri teplote miestnosti a za miešania, aby sa získala úplne homogénna suspenzia.
Výsledná suspenzia sa potom naraz pridá do 500 ml roztoku methoxycelulózy (0,075 72 vo vode a miešanie zmesi pokračuje m i e s tn osti (rýc h1 osť miešan i a P00 ; a pravidelne sleduje, priemerne asi 90 minút pri teplote o t Z m i.n)» V ý v o j e m u 1 z i e k a ž d ý c h 3 0 m i n tú t, odoberan im vzoriek k on t r o 1 o u m i k r o g u 1 i č i e k p o d m i k r o s k o p o m,
A k o n á h 1 e s a u k o n č í m i e š a n i e ( z m e n š tí v a n i e v e ľ k o s t i m i k r o g u 1 i č i e k s a s t a b i 1 i z uje) , p r i d á s a u v e d e n á' e m u 1 z i a n a ľ a z do 2 litrov vody udržovanej približne na teplote 10 °G, načo sa zmes mieša, až sa úplne? zhomogenizuje.
7. reakčnej zmesi sa izolujú mikroguličky F'LGA, ktoré sa vyčistia nasleduúcim odstreďovaním striedajúcim sa s; premývaním vodou» Nakoniec sa mikroguličky odfiltrujú a vysušia pri zníženom tlaku» Získa sa takto 1,61 g (výťažok 80 ’Á ) m i I'·: r o g u 1 i č i. e k F' I.... G A, k t o r é o b s a h u j ú v i a c a k o 94 7. č a s t i c s P ľ i e? m e r o m m e n š í m a k o 10 0 m i k r ó n o v (m a x „ 5 5 a ž 8 5 m i. k r ó n o v ) „
Analýzou (rozpúšťaním hmoty F'LGA, ex trakciou a stanovením peptidu pomocou H F’L C - vysokotlakovej kvapalnej c h r o m a t o g i- a f i e) s a z i s t í , ž e o b s a h rn i k r o g u I i ŕ: i e k v p a m o á t e j e 9,0 5 7. h m o t n o s t n ý c h (t e o r e t i c k y 10 7„) „
Takto získané mikrogličky sa potom podrobia sterilizácií paprskami gama a prevedú sa do suspenzie vo vhodnom sterilnom nosiči» Testy in vivo (meranie hodnoty sanguinového t e s t o s t. e r ó n u u s a m c o v k ľ ý s) p o t v r d z u j ú p r a v i d e Iné u v o 1 ň o v a n i e a k t í v n e j 1 á t k y ,,
Príklad 2
Postupuje sa presne ako v príklade 1, pričom sa použije 0, 634 g p a m o á t u a n a .1 ó g u L H R H n a 1,3 6 é g P' L. G A 7 5 s .2 5,,
Z í s k a s a 1,7 0 g m i k r o g 1 i č i e k P L. G A (v ý ť a Sok 3 5 Z ) „
Obsah mikroguličiek v pamoáte je 18,3 Z (teoret. 20 Z).
Takto získané mikroguličky sa potom sterilizujú gama paprskami a prevedú sa do suspenzie vo vhodnom sterilnom nosiči» Testy in v;i.vo (meraním množstva analógu v sanquinovom s é r e s a m c o v k r ý s) s a. p o t. v r d z u j e, n a s t á v a p r a v i. d e 1 n é uvoľňovanie biologicky významného množstva aktívnej látky v
P ri e b e hu n a j m e n ej 24 n a s 1 e d u j ú c: i c h ú d a j o c: h „ d n í T i e t o v ý s 1 e d k y zhrnuté v
Doba (dni)
-i- 3 dni 1
M n o ž s t. v o p e p t i 47, 1
48,9 ((n g /1. )
14 1 ó
46, 9 50,4 40, 1 42, 1 29, S •-3, O
25,6 .:: .. . . : . „. .
-kú....\;i;ý?Tiéts\;vý'síedkv '-sú·· potvrdené tiež sneIýzami vrobenými ne .. . s vieratách· u?5mrtenýc h tridsiateho. .dna. (D30) n strata hmotriosti testikúl najmenej SO í - straty hmotnosti semi na 1 nyo h vesikúl najmenej 90 %.
ľ“T“P'rl'kta3'P3“““’_.“ ľ .ľ 033 t --····-- -....... Opakuje sa postup podľa príkladu 1, pričom sa použijú 3 g octanu· anál ó g u L.HRH vzorra
Ac—D—Na 1 r-D-pC I Pne.....D—T r pr-Ser—Ty r- D—C i t.....Leu--Ary.....P r o.....D—A i a-NHy
F’ o pre m e n s n í u v e d e n é h o o c: t a n u n a p ľ í s i u O n ý p a m c;: á t a nás 1 ednom--z pracovan í , ako je uvedené v príklade 1, sa získajú mikroyuličky no í y márne ho materiál n- kto-'á majú rovnaká • ’ c harak tenisti k y 'ako bolo uvedené vpredu,,
Claims (7)
- F' ftTENTOVÉ N í P O K Y * U cr cej3.íí vom’ í „ Znie s u r č e n A k p r e cl 1 ž e n é m u a k o n t r o 1 o v a n é í n u u v o 1 ή o v a n .i. u liečivej peptide vej látky vzorca .1 7'A c: - D - N a 1 - D.....p C1P h e ·- R3 - S e r - T y ľ -1 j -- C i t - L. e u - A r g - P r o.....D.....A1 a - N Ha v ktorom R3 znamená D~Pal alebo D-Trp, v y 2 n a č u j ú c: i s a t ý m , že je vo forme mikroguličiek 2 polymárneho biodegraclovatelného materiálu, ktorý obsahuje soľ peptidu. vzorca I nerozpustnú, vo vode.
- 2„ Zmes podľa nároku .t, v y s n a č u j ú c a s a t ý m , že peptidovou soľou nerozpustnou vo vode je? pamoát, t a n n á t, s t. e a r á t. a 1 e ta o p za 1 m i t á t.
- 3» Zmes podľa nároku 1 alebo 2, v y z n a č u j ú c a s a t ý m , že polymárnym biodegrádováteľným materiálom je poly 1 aktid, poly g.1 ykolid alebo kopolymár kyseliny mliečnej s gly kolovou..
- 4. Zmes; podľa nároku 3, v y s n a č: u j ú c a s a t ý m , že kopol y má r kyseliny mliečnej s gly kolovou, je? k o p o 1. y m á r k y s e 1 i n y L - a 1 e b o D, I.... - m 1 i e č n e j , k t o r ý o b s a h u j e 4 5 a ž 90 mol 7. jednotiek kyseliny mliečnej, respektíve 55 až 10 m o 1 Z k yse1 i n y g 1y k o1ovej.
- 5. Zmes podľa niektorého 2 nárokov í až 4, v y 2 n a č u-
<· j ú c: a s a t. ý m , že je vo forme m i k r o g u 1 i č i e k ! < o po 1 y - má r u k y s e 1 i n y m .1. i e č n e j s kyselinou glykolovou v mó1ovom pomere 75 s 25, ktorý obs ahuje aspoň 5 Z hmotnostnýc h pamoátu peptidu vzorca I. 6» Použitie 2mesi podľa niektorá ho 2 nárokov : L až 5 k Ρ r í pravé s u s p e n 2 i e u r č e n e j k. p o d á v a n i u p a r e n t. e r á 1 n o u c e s t o u,. - 7. Zpôsob prípravy zmesi podľa nároku 1, v y 2 n a č u™ j ú o a sa t ý m , ž e s aa) soľ peptidu. vzorca I rozpustná vo vode premení na soľ peptidu nerozpustnú vo vode,b) uvádzaný peptid, respektíve soľ peptidu nerozpustná vo . „y.oci.e.. sa.... obsahujtó stave, .prevedie .do. štiepe'j s. i e. v. organ ickom . pros..trsd í - ktoré polymérny biedegradevate 1ný materiál v rozpi, stencmc) uvedená or gáni c: k á suspenzia sa di.spergu.je vo vednom prostredí sa súvislej fázy výslednej emulzie.d 5 uvedená 'emulzia' sa prostredia, a nakoniec sa z. vznik n u t é m i k i' o g i j 1 i d .k y ,S„ Zpôsob podľa nároku 7, p r” i d á d o kvapalnej .n a d ta y t k u v o d n é h o fázv izolujú takto z n a d -í j ú c: i.t - ý m - , d e pred ' pridaním emulzie olej vo vode do nadbytku vodného prostredia sa organické rozpústad i o, tvoriace olejovú .'fázu, ' diastodne odparí, v, Zpôsob podľa nároku 7, v y z n a d u j ú z:' i z; a tým , d e sa ako soľ peptidu nerozpustríá vo vode používa P a m c á t, o a n n a t, s t e a r s t a i e c o p a .t r i i t Z; c«
- 10. Zpôsob podľa niektorého z nárokizv 7 ad y, v y z n a ·S e p o 1 y m é r- y m b i o .j e g r a d o v a t s 1 n ý mP o 1 y g 1. y k o .1 i d a I p bu k o p o 1 y m é r č u j (j c i s a materiálom je po 1 yl ak t id , kyselín mliečnej a glykolovej, 11, Zpôsob podľa nároku 10ľ tým, d e kopolymé'· kyseliny L-·- alebo d........mliednej obsahuje45 ad 90 mol Z jednotiek kyseliny mliečnej- respektíve j O ad 5 5 i n o 1 a je tí n o t i e k k y s e 1 i. n y g i y k o 1 o vej.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH2178/91A CH683149A5 (fr) | 1991-07-22 | 1991-07-22 | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
PCT/CH1992/000146 WO1993001802A1 (fr) | 1991-07-22 | 1992-07-15 | Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
SK38293A3 true SK38293A3 (en) | 1993-08-11 |
SK280612B6 SK280612B6 (sk) | 2000-05-16 |
Family
ID=4227716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK382-93A SK280612B6 (sk) | 1991-07-22 | 1992-07-15 | Zmes na predĺžené a kontrolované uvolňovanie lieči |
Country Status (40)
Country | Link |
---|---|
US (2) | US5445832A (sk) |
JP (2) | JP2842736B2 (sk) |
KR (1) | KR930702018A (sk) |
CN (1) | CN1054543C (sk) |
AT (2) | AT408609B (sk) |
AU (2) | AU652844B2 (sk) |
BE (2) | BE1005697A5 (sk) |
BR (1) | BR9205375A (sk) |
CA (2) | CA2074322C (sk) |
CH (2) | CH683149A5 (sk) |
CZ (1) | CZ287585B6 (sk) |
DE (3) | DE4223284C2 (sk) |
DK (2) | DK176219B1 (sk) |
EE (1) | EE03014B1 (sk) |
ES (2) | ES2037621B1 (sk) |
FI (2) | FI106925B (sk) |
FR (2) | FR2680109B1 (sk) |
GB (2) | GB2257909B (sk) |
GR (2) | GR1002548B (sk) |
HR (1) | HRP920229A2 (sk) |
HU (1) | HU218203B (sk) |
IE (2) | IE69967B1 (sk) |
IL (2) | IL102590A (sk) |
IT (2) | IT1259891B (sk) |
LU (2) | LU88150A1 (sk) |
MX (1) | MX9204268A (sk) |
NL (2) | NL194577C (sk) |
NO (2) | NO304136B1 (sk) |
NZ (1) | NZ243643A (sk) |
PH (1) | PH31564A (sk) |
PL (1) | PL169387B1 (sk) |
PT (2) | PT100712B (sk) |
RU (1) | RU2103994C1 (sk) |
SE (2) | SE512670C2 (sk) |
SI (1) | SI9200152B (sk) |
SK (1) | SK280612B6 (sk) |
TW (1) | TW260610B (sk) |
UA (1) | UA35569C2 (sk) |
WO (1) | WO1993001802A1 (sk) |
ZA (2) | ZA925485B (sk) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
DE4320201A1 (de) * | 1993-06-18 | 1995-01-12 | Asta Medica Ag | Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
KR0162872B1 (ko) * | 1996-04-01 | 1998-12-01 | 김은영 | 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법 |
US20020111603A1 (en) * | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
EP1073419A4 (en) * | 1998-03-18 | 2009-03-25 | Univ Technology Corp | COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE. |
SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US20070009605A1 (en) * | 1998-07-23 | 2007-01-11 | Ignatious Francis X | Encapsulation of water soluble peptides |
WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
EP1240896A3 (en) * | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
GB2344519B (en) * | 1998-12-07 | 2004-05-19 | Johnson & Johnson Medical Ltd | Sterile therapeutic compositions |
IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
US6682724B2 (en) | 1999-02-23 | 2004-01-27 | Arch Chemcials, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
US6204308B1 (en) | 1999-03-01 | 2001-03-20 | Novartis Ag | Organic compounds |
US6317623B1 (en) * | 1999-03-12 | 2001-11-13 | Medrad, Inc. | Apparatus and method for controlling contrast enhanced imaging procedures |
AU3556400A (en) | 1999-03-17 | 2000-10-04 | Novartis Ag | Pharmaceutical compositions |
EP1044683A1 (en) * | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | One-step dispersion method for the microencapsulation of water soluble substances |
ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
ATE361057T1 (de) | 2000-12-21 | 2007-05-15 | Alrise Biosystems Gmbh | Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
CN1558755A (zh) * | 2001-09-26 | 2004-12-29 | ���ع��ʹ�˾ | 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒 |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
KR100885070B1 (ko) * | 2002-05-08 | 2009-02-25 | 재단법인서울대학교산학협력재단 | Plga에 특이적으로 부착하는 올리고 펩타이드 |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7314859B2 (en) * | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
ATE365174T1 (de) | 2003-01-28 | 2007-07-15 | Microbia Inc | Zusammensetzungen zur behandlung von gastrointestinalen störungen |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CN1938040A (zh) * | 2003-03-05 | 2007-03-28 | Pr药品有限公司 | 缩宫素控释制剂及其应用方法 |
US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
CA2580313C (en) | 2004-07-19 | 2016-03-15 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US8541028B2 (en) | 2004-08-04 | 2013-09-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
ES2255426B1 (es) | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
EP1838305A1 (en) * | 2005-01-21 | 2007-10-03 | Richard H. Matthews | Radiosensitizer formulations comprising nitrohistidine derivatives |
MX2007013213A (es) * | 2005-04-25 | 2007-12-12 | Amgen Inc | Composiciones de liberacion prolongada de peptidos biodegradables que contienen porogenos. |
SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
MX2007015183A (es) * | 2005-06-14 | 2008-02-19 | Baxter Int | Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco. |
EP1954245A2 (en) * | 2005-11-15 | 2008-08-13 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
WO2007071395A1 (en) | 2005-12-22 | 2007-06-28 | Novartis Ag | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
EP1983917B1 (en) | 2006-01-27 | 2014-06-25 | Spinal Ventures, LLC | Low pressure delivery system for delivering a solid and liquid mixture into a target site for medical treatment |
KR100722607B1 (ko) | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
US8211905B1 (en) | 2007-05-22 | 2012-07-03 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties |
US20080293695A1 (en) | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
US7858663B1 (en) | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US10183001B1 (en) | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
US9421266B2 (en) | 2007-05-22 | 2016-08-23 | Pisgah Laboratories, Inc. | Safety of pseudoephedrine drug products |
US8329720B1 (en) | 2007-05-22 | 2012-12-11 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties |
US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
EP2500014B1 (en) * | 2007-06-06 | 2018-08-08 | Debiopharm Research & Manufacturing SA | Slow release pharmaceutical composition made of microparticles |
CN101939023B (zh) | 2007-10-16 | 2016-08-03 | 百康有限公司 | 可经口给药的固体药物组合物及其方法 |
CN101873797A (zh) | 2007-10-19 | 2010-10-27 | 萨可德公司 | 用于治疗糖尿病性视网膜病的组合物和方法 |
CA2709712C (en) | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
NZ595204A (en) | 2009-03-09 | 2014-11-28 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
ES2363965B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
JP2013515719A (ja) | 2009-12-23 | 2013-05-09 | デフィアンテ・ファルマセウティカ・ソシエダデ・アノニマ | 循環器疾患の処置に有用な組み合わせ組成物 |
ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
JP6092849B2 (ja) | 2011-05-04 | 2017-03-08 | バランス セラピューティックス, インコーポレイテッドBalance Therapeutics, Inc. | ペンチレンテトラゾール誘導体 |
WO2013072767A1 (en) | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
WO2013150386A2 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
EP2833881A1 (en) | 2012-04-04 | 2015-02-11 | Pronova BioPharma Norge AS | Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof |
DK2851085T3 (da) * | 2012-05-14 | 2019-09-09 | Teijin Ltd | Proteinsammensætning steriliseret ved stråling |
CN104797574B (zh) | 2012-07-25 | 2019-11-22 | 原生质生物科学股份有限公司 | Lfa-1抑制剂及其多晶型物 |
JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
EP3578170A1 (en) | 2013-02-28 | 2019-12-11 | Basf As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US20160220630A1 (en) | 2013-10-10 | 2016-08-04 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
CN108884130B (zh) | 2016-01-11 | 2022-09-13 | 博士医疗爱尔兰有限公司 | 用于治疗溃疡性结肠炎的制剂和方法 |
CN111315365A (zh) | 2017-09-26 | 2020-06-19 | 纳奥米有限公司 | 用于通过双乳液技术制备微粒的方法 |
CN111712240A (zh) | 2017-12-06 | 2020-09-25 | 巴斯夫股份公司 | 用于治疗非酒精性脂肪性肝炎的脂肪酸衍生物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2010115A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
JPS523342B2 (sk) * | 1972-01-26 | 1977-01-27 | ||
US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
US4622244A (en) * | 1979-09-04 | 1986-11-11 | The Washington University | Process for preparation of microcapsules |
US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4341767A (en) * | 1980-10-06 | 1982-07-27 | Syntex Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
ATE61935T1 (de) * | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
US4666704A (en) * | 1985-05-24 | 1987-05-19 | International Minerals & Chemical Corp. | Controlled release delivery system for macromolecules |
IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5000886A (en) * | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
CH672887A5 (sk) * | 1987-10-14 | 1990-01-15 | Debiopharm Sa | |
US5187150A (en) * | 1987-10-14 | 1993-02-16 | Debiopharm S.A. | Polyester-based composition for the controlled release of polypeptide medicinal substances |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
EP0471036B2 (en) * | 1989-05-04 | 2004-06-23 | Southern Research Institute | Encapsulation process |
HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
CH679207A5 (sk) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
CH681425A5 (sk) * | 1990-11-14 | 1993-03-31 | Debio Rech Pharma Sa | |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
-
1991
- 1991-07-22 CH CH2178/91A patent/CH683149A5/fr not_active IP Right Cessation
-
1992
- 1992-07-15 DE DE4223284A patent/DE4223284C2/de not_active Expired - Lifetime
- 1992-07-15 DE DE9219084U patent/DE9219084U1/de not_active Expired - Lifetime
- 1992-07-15 CH CH882/93A patent/CH683592A5/fr not_active IP Right Cessation
- 1992-07-15 DE DE4223282A patent/DE4223282A1/de not_active Ceased
- 1992-07-15 WO PCT/CH1992/000146 patent/WO1993001802A1/fr active IP Right Grant
- 1992-07-15 HU HU9301186A patent/HU218203B/hu not_active IP Right Cessation
- 1992-07-15 PL PL92298504A patent/PL169387B1/pl not_active IP Right Cessation
- 1992-07-15 BR BR9205375A patent/BR9205375A/pt not_active Application Discontinuation
- 1992-07-15 CZ CZ1993660A patent/CZ287585B6/cs not_active IP Right Cessation
- 1992-07-15 RU RU93004902A patent/RU2103994C1/ru not_active IP Right Cessation
- 1992-07-15 SK SK382-93A patent/SK280612B6/sk unknown
- 1992-07-15 UA UA93004548A patent/UA35569C2/uk unknown
- 1992-07-16 US US07/915,478 patent/US5445832A/en not_active Expired - Lifetime
- 1992-07-20 HR HR920229A patent/HRP920229A2/xx not_active Application Discontinuation
- 1992-07-20 BE BE9200672A patent/BE1005697A5/fr not_active IP Right Cessation
- 1992-07-20 BE BE9200671A patent/BE1005696A3/fr not_active Expired - Fee Related
- 1992-07-21 ES ES9201522A patent/ES2037621B1/es not_active Expired - Fee Related
- 1992-07-21 AT AT0148892A patent/AT408609B/de not_active IP Right Cessation
- 1992-07-21 FI FI923321A patent/FI106925B/fi not_active IP Right Cessation
- 1992-07-21 SE SE9202213A patent/SE512670C2/sv not_active IP Right Cessation
- 1992-07-21 GB GB9215479A patent/GB2257909B/en not_active Expired - Lifetime
- 1992-07-21 ZA ZA925485A patent/ZA925485B/xx unknown
- 1992-07-21 LU LU88150A patent/LU88150A1/fr unknown
- 1992-07-21 ZA ZA925486A patent/ZA925486B/xx unknown
- 1992-07-21 IL IL102590A patent/IL102590A/xx not_active IP Right Cessation
- 1992-07-21 NZ NZ243643A patent/NZ243643A/en unknown
- 1992-07-21 NL NL9201310A patent/NL194577C/nl not_active IP Right Cessation
- 1992-07-21 NO NO922885A patent/NO304136B1/no not_active IP Right Cessation
- 1992-07-21 GR GR920100323A patent/GR1002548B/el not_active IP Right Cessation
- 1992-07-21 IT ITBS920092A patent/IT1259891B/it active IP Right Grant
- 1992-07-21 SI SI9200152A patent/SI9200152B/sl unknown
- 1992-07-21 GB GB9215480A patent/GB2257973B/en not_active Expired - Fee Related
- 1992-07-21 TW TW081105749A patent/TW260610B/zh active
- 1992-07-21 CN CN92109509A patent/CN1054543C/zh not_active Expired - Fee Related
- 1992-07-21 PT PT100712A patent/PT100712B/pt not_active IP Right Cessation
- 1992-07-21 GR GR920100322A patent/GR1001446B/el unknown
- 1992-07-21 AU AU20437/92A patent/AU652844B2/en not_active Expired
- 1992-07-21 IT ITBS920093A patent/IT1259892B/it active IP Right Grant
- 1992-07-21 IL IL102591A patent/IL102591A/xx not_active IP Right Cessation
- 1992-07-21 NL NL9201309A patent/NL194576C/nl not_active IP Right Cessation
- 1992-07-21 IE IE922366A patent/IE69967B1/en not_active IP Right Cessation
- 1992-07-21 DK DK199200939A patent/DK176219B1/da not_active IP Right Cessation
- 1992-07-21 FI FI923320A patent/FI105318B/fi not_active IP Right Cessation
- 1992-07-21 LU LU88151A patent/LU88151A1/fr unknown
- 1992-07-21 PT PT100713A patent/PT100713B/pt not_active IP Right Cessation
- 1992-07-21 PH PH44682A patent/PH31564A/en unknown
- 1992-07-21 IE IE922367A patent/IE71199B1/en not_active IP Right Cessation
- 1992-07-21 CA CA002074322A patent/CA2074322C/en not_active Expired - Fee Related
- 1992-07-21 NO NO922886A patent/NO304057B1/no unknown
- 1992-07-21 FR FR929208992A patent/FR2680109B1/fr not_active Expired - Fee Related
- 1992-07-21 FR FR9208991A patent/FR2679450B1/fr not_active Expired - Lifetime
- 1992-07-21 DK DK199200938A patent/DK176218B1/da not_active IP Right Cessation
- 1992-07-21 MX MX9204268A patent/MX9204268A/es not_active IP Right Cessation
- 1992-07-21 ES ES09201523A patent/ES2050070B1/es not_active Expired - Fee Related
- 1992-07-21 SE SE9202212A patent/SE512609C2/sv not_active IP Right Cessation
- 1992-07-21 JP JP4194313A patent/JP2842736B2/ja not_active Expired - Lifetime
- 1992-07-21 AU AU20436/92A patent/AU651711B2/en not_active Ceased
- 1992-07-21 CA CA002074320A patent/CA2074320C/en not_active Expired - Lifetime
- 1992-07-21 AT AT0148992A patent/AT403348B/de not_active IP Right Cessation
- 1992-07-21 JP JP19431092A patent/JP3600252B2/ja not_active Expired - Fee Related
-
1993
- 1993-03-22 KR KR1019930700851A patent/KR930702018A/ko not_active IP Right Cessation
-
1994
- 1994-03-16 US US08/210,097 patent/US5637568A/en not_active Expired - Fee Related
- 1994-11-21 EE EE9400282A patent/EE03014B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK38293A3 (en) | Copposition for the substained and controlled release of a medicinal peptidecontaining substance and preparation method thereof | |
US4675189A (en) | Microencapsulation of water soluble active polypeptides | |
RU2178695C2 (ru) | Микрокапсулы, содержащие рисперидон, фармацевтическая композиция и способы их получения | |
HU196703B (en) | Process for producing biologically decomposing lactic acid and/or glycolic acid homo- or copolymers usable for pharmaceutical purposes | |
DE69624426T2 (de) | Verfahren zur Herstellung einer Zubereitung mit verzögerter Freisetzung | |
KR100914113B1 (ko) | 수불용성이고 활성인 안정한 나노입자 및 중쇄트리글리세리드(mct)와 같은 부형제를 포함하는수분산액 | |
LV10055B (en) | Prolonged release preparation and polymers thereof | |
CZ303134B6 (cs) | Polymerní formulace leuprolidu pro podání se zlepšenou úcinností | |
US20040009226A1 (en) | Injectable system for controlled drug delivery | |
JP4927729B2 (ja) | 性腺刺激ホルモン放出ホルモンアンタゴニスト | |
WO2010009291A1 (en) | Process for preparing microparticles containing bioactive peptides | |
HUE031550T2 (en) | Slow release drug formulation from microparticles | |
US20020106406A1 (en) | Crystallizable/non-crystallizable polymer composites | |
JP3490171B2 (ja) | 生体内分解性ポリマーの末端カルボキシル基におけるエステル | |
JP3524195B2 (ja) | 徐放性製剤用基剤 |